Almac Supports Clients in Response to New, Stringent, FDA Heavy Metal Mandates by Investing in ICP-MS Equipment
As the Industry faces the tightest ever new heavy metal mandates from FDA, stipulating the control and documentation, where appropriate, of all elemental impurities in drug products, drug substances and excipients, Almac has invested in state of the art ICP-MS equipment at their European Headquarters, Craigavon, UK to future-proof clients’ drug development programmes to satisfy these requirements and support their clients with these demanding new regulations.
In compliance with USP <232 & 233>, EP (2.4.20), and ICH Q3D, all components, processes, packaging and final product must be tested for the presence of heavy metals, and inductively coupled plasma mass spectrometry (ICP-MS) is the most suitable technique to meet the requirements of these, and future regulatory requirements.
Therefore, to prepare for current and future implications of these mandates, Almac has built on its mass spectrometry capabilities, investing in the industry leading Agilent 7900 ICP-MS and Mars microwave digestion technology. This ICP-MS instrument offers exceptional matrix tolerance and unmatched interference and false positives removal with a He collision cell. It includes Ultra High Matrix Introduction (UHMI) technology that enables routine measurement of samples containing up to 25% total dissolved solids (TDS), 100 times higher than the traditional matrix limit for ICP-MS. The high organic kit allows the introduction of samples dissolved in pure solvent, samples which previously required microwave digestion.
Linda McCausland, Head of Almac’s Physical Sciences and Spectroscopy stated: “These mandates dictate a significant shift in the attitude of FDA towards heavy metals in all aspects of drug development. Customer focus is our top priority, and the enhanced services offered from this additional investment will provide assurance for our clients whilst complying with the regulatory guidelines.”
The acquisition of this new instrument complements Almac’s current suite of LC-MS and GC-MS technologies, which were part of a recent $2 million investment in Almac’s analytical laboratories.
Stephen Barr, Managing Director of Almac Sciences added: “We are delighted we can support our customers through the challenges of FDA’s stringent new mandates for heavy metal analysis. This investment reinforces our commitment to fully support our clients through every aspect of their drug development programmes.”
Agilent Technologies were chosen as the preferred vendor to supply the mass spectrometers to Almac. Declan Murray, Sales Manager noted: “Agilent Technologies are delighted that Almac has invested in the industry leading Agilent 7900 ICP-MS. Agilent has a long and successful relationship with Almac and we’re looking forward to working with their analytical team to strengthen this relationship even further.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance